 | Up a level |
Kim, Dong-Wan, Tan, Daniel Shao-Weng, Aix, Santiago Ponce, Sequist, Lecia V., Smit, Egbert F., Hida, Toyoaki, Yang, James Chih-Hsin, Felip, Enriqueta, Seto, Takashi, Grohe, Christian, Wolf, Juergen, Ko, Jinnie, Diallo, Mariama, Pultar, Philippe, Giovannini, Monica and Kim, Sang-We (2018). Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Tan, Daniel Shao-Weng, Lee, Dae Ho, Soo, Ross, Michels, Sebastian, Barlesi, Fabrice, Sangha, Randeep, Le Gac, Fabienne, Pultar, Philippe, Glaser, Sabine, Cui, Xiaoming, Akimov, Mikhail and Felipe, Enriqueta (2017). Phase lb Results from a Study of Capmatinib (INC280)+EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC). J. Thorac. Oncol., 12 (1). S. S1264 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380